小剂量尿激酶联合低分子肝素治疗急性进展性脑梗死疗效及对神经功能的影响

摘要

Objective To analyze the effect of small dose urokinase combined with low molecular heparin on efficacy and neurological function in acute progressive cerebral infarction patients.Methods A total of 102 acute progressive cerebral infarction patients were divided into observation group and control group according to the order of treatment, with 51 cases in each group.Patients of two groups admitted to the hospital were given conventional targeted treatment for brain protection, the control group was additionally given low molecular heparin, and the observation group was given small dose of urokinase intravenous infusion on the basis of the control group.The treatment efficacy, the incidence of adverse reactions during the treatment, the changes of coagulation indicators and nerve function were compared between the two groups.Results The total efficacy rate of the observation group was significantly higher than that of the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05);Before treatment, blood coagulation indicators (PT, APTT, INR, FIB) and neurological deficit scores showed no significant difference (P>0.05);After treatment, the observation group had higher PT, and APTT INR, lower FIB and neurological deficit scores than the control group (P<0.05).Conclusion Low dose of urokinase combined with low molecular heparin can improve coagulation state and therapeutic efficacy of acute cerebral infarction patients and promote the recovery of neurological function.%目的 分析小剂量尿激酶联合低分子肝素治疗急性进展性脑梗死患者的临床疗效及对神经功能的影响.方法 将102例急性进展性脑梗死患者根据就诊顺序分为观察组和对照组各51例.2组患者入院后均按照常规行脑神经保护等对症治疗,对照组在此基础上给予低分子肝素,观察组在对照组基础上给予小剂量尿激酶静脉滴注.比较2组的治疗效果、治疗过程中不良反应发生率及治疗前后凝血指标和神经功能的变化.结果 观察组治疗的总有效率显著高于对照组(P<0.05);2组患者治疗过程中不良反应发生率无显著差异(P>0.05);2组治疗前凝血指标(PT、APTT、INR、FIB)及神经功能缺损得分均无显著差异(P>0.05);观察组治疗后PT、APTT及INR均显著高于对照组(P<0.05);观察组治疗后FIB显著低于对照组(P<0.05);观察组治疗后神经功能缺损评分仍显著低于对照组(P<0.05).结论 小剂量尿激酶联合低分子肝素能有效改善急性进展性脑梗死患者的凝血状态,提高治疗效果和促进神经功能恢复.